Recommendations of the Panel on Cost-effectiveness in Health and Medicine - PubMed (original) (raw)
Review
. 1996 Oct 16;276(15):1253-8.
Affiliations
- PMID: 8849754
Review
Recommendations of the Panel on Cost-effectiveness in Health and Medicine
M C Weinstein et al. JAMA. 1996.
Abstract
Objective: To develop consensus-based recommendations for the conduct of cost-effectiveness analysis (CEA). This article, the second in a 3-part series, describes the basis for recommendations constituting the reference case analysis, the set of practices developed to guide CEAs that inform societal resource allocation decisions, and the content of these recommendations.
Participants: The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, was convened by the US Public Health Service (PHS).
Evidence: The panel reviewed the theoretical foundations of CEA, current practices, and alternative methods used in analyses. Recommendations were developed on the basis of theory where possible, but tempered by ethical and pragmatic considerations, as well as the needs of users.
Consensus process: The panel developed recommendations through 2 1/2 years of discussions. Comments on preliminary drafts prepared by panel working groups were solicited from federal government methodologists, health agency officials, and academic methodologists.
Conclusions: The panel's methodological recommendations address (1) components belonging in the numerator and denominator of a cost-effectiveness (C/E) ratio; (2) measuring resource use in the numerator of a C/E ratio; (3) valuing health consequences in the denominator of a C/E ratio; (4) estimating effectiveness of interventions; (5) incorporating time preference and discounting; and (6) handling uncertainty. Recommendations are subject to the ¿rule of reason,¿ balancing the burden engendered by a practice with its importance to a study. If researchers follow a standard set of methods in CEA, the quality and comparability of studies, and their ultimate utility, can be much improved.
Comment in
- Cost-effectiveness analyses of statistically ineffective treatments.
Trippoli S, Messori A. Trippoli S, et al. JAMA. 1998 Dec 16;280(23):1992-3. doi: 10.1001/jama.280.23.1992-a. JAMA. 1998. PMID: 9863846 No abstract available.
Similar articles
- The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. Russell LB, et al. JAMA. 1996 Oct 9;276(14):1172-7. JAMA. 1996. PMID: 8827972 Review. - Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.
Siegel JE, Weinstein MC, Russell LB, Gold MR. Siegel JE, et al. JAMA. 1996 Oct 23-30;276(16):1339-41. doi: 10.1001/jama.276.16.1339. JAMA. 1996. PMID: 8861994 Review. - Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.
Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Siegel JE, et al. Pharmacoeconomics. 1997 Feb;11(2):159-68. doi: 10.2165/00019053-199711020-00005. Pharmacoeconomics. 1997. PMID: 10172935 Review. - Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I, Coast J, Brown J. Griebsch I, et al. Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127. Pediatrics. 2005. PMID: 15867026 Review. - Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Sanders GD, et al. JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195. JAMA. 2016. PMID: 27623463
Cited by
- Hemiarthroplasty vs. internal fixation for nondisplaced femoral neck fracture in mainland China: a cost-effectiveness analysis.
Wang S, Tan L, Sheng B. Wang S, et al. Front Surg. 2024 Aug 29;11:1437290. doi: 10.3389/fsurg.2024.1437290. eCollection 2024. Front Surg. 2024. PMID: 39268494 Free PMC article. - Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT.
Cooper KG, Bhattacharya S, Daniels JP, Cheed V, Gennard L, Leighton L, Pirie D, Melyda M, Monahan M, Weckesser A, Roberts T, Denny E, Ocansey L, Stubbs C, Cox E, Jones G, Clark TJ, Saridogan E, Gupta JK, Critchley HO, Horne A, Middleton LJ. Cooper KG, et al. Health Technol Assess. 2024 Sep;28(55):1-77. doi: 10.3310/SQWY6998. Health Technol Assess. 2024. PMID: 39259620 Free PMC article. Clinical Trial. - Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis.
Kao SZ, Sangha K, Fujiwara N, Hoshida Y, Parikh ND, Singal AG. Kao SZ, et al. EClinicalMedicine. 2024 Aug 13;75:102755. doi: 10.1016/j.eclinm.2024.102755. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39234558 Free PMC article. - Adoption of a Societal Perspective in Economic Evaluations of Musculoskeletal Disorders: A Conceptual Paper.
Fatoye F, Gebrye T, Nherera L, Trueman P. Fatoye F, et al. J Mark Access Health Policy. 2024 Aug 12;12(3):216-223. doi: 10.3390/jmahp12030018. eCollection 2024 Sep. J Mark Access Health Policy. 2024. PMID: 39193540 Free PMC article. - Re-evaluating the impact and cost-effectiveness of pneumococcal conjugate vaccine introduction in 112 low-income and middle-income countries in children younger than 5 years: a modelling study.
Chen C, Ang G, Akksilp K, Koh J, Scott JAG, Clark A, Jit M. Chen C, et al. Lancet Glob Health. 2024 Sep;12(9):e1485-e1497. doi: 10.1016/S2214-109X(24)00232-8. Lancet Glob Health. 2024. PMID: 39151983 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources